Chugai Pharmaceutical Co., Ltd. Share Price
Stocks
4519
JP3519400000
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
11:15:16 17/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 6,672.00 JPY | +3.51% |
|
+3.97% | -19.05% |
| 21/08 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 18/08 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 10,60600Cr 6.84TCr 5.93TCr 5.6TCr 5.08TCr 9.53TCr 6,56000Cr 9.59TCr 67TCr 26TCr 3,32700Cr 26TCr 25TCr | P/E 2026 * |
21x | P/E 2027 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 9,69600Cr 6.25TCr 5.42TCr 5.12TCr 4.65TCr 8.71TCr 5,99700Cr 8.76TCr 61TCr 24TCr 3,04200Cr 23TCr 23TCr | EV / Sales 2026 * |
6.98x | EV / Sales 2027 * | 6.18x |
| Free-Float |
38.12% | Yield 2026 * |
2.11% | Yield 2027 * | 2.41% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4519 | Delayed | |
OTC Markets
| CHGCF | Delayed | |
|
Mexican S.E.
| 4519 N | End-of-day quote | |
|
Tradegate
| CUP | Real-time | |
|
Deutsche Boerse AG
| CUP | Delayed | |
|
Börse Stuttgart
| CUP | Delayed | |
|
Boerse Muenchen
| CUP | Real-time |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | +3.52% | ||
| 1 week | +3.97% | ||
| Current month | -3.47% | ||
| 1 month | -2.78% | ||
| 3 months | -12.77% | ||
| 6 months | -28.39% | ||
| Current year | -19.05% |
| 1 week | 6,293 |  | 6,684 |
| 1 month | 6,293 | | 7,141 |
| Current year | 6,293 | | 10,700 |
| 1 year | 6,250 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 01/03/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 28/03/2024 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 01/03/2020 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 28/03/2024 |
| Director/Board Member | 51 | 01/03/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.51% | +3.97% | -0.73% | +49.69% | 6.84TCr | |
| +0.15% | +1.21% | +48.79% | +97.65% | 1,01400Cr | |
| +0.03% | +0.07% | +51.47% | +65.55% | 64TCr | |
| -0.20% | +4.62% | +21.39% | +72.57% | 46TCr | |
| +0.53% | +4.26% | +40.29% | +38.70% | 35TCr | |
| +0.39% | +2.35% | +17.96% | +23.87% | 27TCr | |
| +0.17% | +4.17% | +6.96% | +10.93% | 25TCr | |
| +0.19% | -3.81% | +37.81% | +44.35% | 20TCr | |
| -1.20% | -5.64% | -24.09% | -59.10% | 19TCr | |
| +0.94% | +1.39% | +33.21% | +95.16% | 18TCr | |
| Average | +0.45% | +0.82% | +23.31% | +43.94% | 36.35TCr | |
| Weighted average by Cap. | +0.18% | +1.38% | +33.72% | +59.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,38800Cr 895.1Cr 775.7Cr 733.16Cr 665.6Cr 1.25TCr 86TCr 1.25TCr 8.75TCr 3.38TCr 44TCr 3.36TCr 3.29TCr | 1,52900Cr 985.74Cr 854.24Cr 807.4Cr 732.99Cr 1.37TCr 95TCr 1.38TCr 9.64TCr 3.72TCr 48TCr 3.7TCr 3.62TCr |
| Net income | 51TCr 326.44Cr 282.89Cr 267.38Cr 242.74Cr 454.95Cr 31TCr 457.67Cr 3.19TCr 1.23TCr 16TCr 1.23TCr 1.2TCr | 58TCr 376.17Cr 325.99Cr 308.11Cr 279.72Cr 524.26Cr 36TCr 527.39Cr 3.68TCr 1.42TCr 18TCr 1.41TCr 1.38TCr |
| Net Debt | -91TCr -586.82Cr -508.53Cr -480.65Cr -436.36Cr -817.83Cr -56TCr -822.72Cr -5.74TCr -2.22TCr -29TCr -2.2TCr -2.16TCr | -1,15100Cr -741.99Cr -643.01Cr -607.75Cr -551.74Cr -1.03TCr -71TCr -1.04TCr -7.26TCr -2.8TCr -36TCr -2.79TCr -2.73TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/26/17 | JP¥6,672.00 | +3.51% | 15,17,200 |
| 16/26/16 | JP¥6,446.00 | -0.83% | 22,25,200 |
| 15/26/15 | JP¥6,500.00 | +1.34% | 19,07,400 |
| 14/26/14 | JP¥6,414.00 | -0.12% | 17,55,500 |
| 11/26/11 | JP¥6,422.00 | +0.06% | 30,08,400 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
